

Supplementary Table 2. Patient disposition to Week 96 in patients with early persistent retinal fluid

Reason for discontinuation	Brolucizumab 6 mg N=82; n (%)	Aflibercept 2 mg N=140; n (%)
Adverse event	1 (1.2)	4 (2.9)
Death	1 (1.2)	3 (2.1)
Lack of efficacy	0 (0.0)	4 (2.9)
Lost to follow-up	2 (2.4)	3 (2.1)
Physician decision	0 (0.0)	1 (0.7)
Progressive disease	0 (0.0)	6 (4.3)
Withdrawal by subject	1 (1.2)	6 (4.3)
Other	2 (2.4)	0 (0.0)
Total	7 (8.5)	27 (19.3)